BI-847325
Cat. No.：YN350192
CAS No. ：1207293-36-4
| 产品名称: | BI-847325 |
| CAS No.: | 1207293-36-4 |
| Chemical Name: | 3-[3-[[[4-[(dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-6-yl]-N-ethyl-2-propynamide |
| Synonyms: | BI-847325;BI847325;3-[3-[[[4-[(Dimethylamino)methyl]phenyl]amino]phenylmethylene]-2,3-dihydro-2-oxo-1H-indol-6-yl]-N-ethyl-2-propynamide;hylpropiolamide;BI 847325;(Z)-3-(3-(((4-((dimethylamino)methyl)phenyl)amino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-et |
| 分子量: | 464.56 |
| 分子式: | C₂₉H₂₈N₄O₂ |
| SMILES: | O=C(NCC)C#CC1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(CN(C)C)C=C3)/C4=CC=CC=C4 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | BI-847325是MEK和极光激酶 (AK)的ATP竞争性双重抑制剂， 对人类MEK2和AK-C的IC50值分别为4和15 nM。 |
| IC50和靶点: | [{name:"MEK2:4 nM (IC50)"},{name: "Aurora C:15 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Phadke, M.S., Sini, P., and Smalley, K.S.M.The novel ATP-competitive MEK/aurora kinase inhibitor BI-847325 overcomes acquired BRAF inhibitor resistance through suppression of Mcl-1 and MEK expressionMol. Cancer Ther.14(6),1354-1364(2015)
